Adial Pharmaceuticals Scheduled, Nasdaq: ADIL

Developing a targeted therapy for alcohol use disorder based on an approved drug.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder ("AUD") using our lead investigational new drug product, AD04, a selective serotonin-3 antagonist. The active ingredient in AD04 is ondansetron, which is also the active ingredient in Zofran, an approved drug for treating nausea and emesis. AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption. We intend to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes. We believe our approach is unique in that it targets the serotonin system and individualizes the treatment of AUD, through the use of genetic screening. We have created an investigational companion diagnostic biomarker test for the genetic screening of patients with certain biomarkers that we believe will benefit from treatment with AD04. Our strategy is to integrate the pre-treatment genetic screening into AD04's label to create a patient-specific treatment in one integrated therapeutic offering. Our goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.
more less
IPO News for Adial Pharmaceuticals
more
IPO Data
IPO File Date 09/07/2017
Offer Price
Price Range $9.00 - $11.00
Offer Shares (mm) 1.4
Deal Size ($mm) $14
IPO Data
IPO Date
Offer Price
Price Range $9.00 - $11.00
Offer Shares (mm) 1.4
Deal Size ($mm) $14
Underwriters
more
Company Data
Headquarters Charlottesville, VA
Founded 2010
Employees 3
Website www.adialpharma.com